Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/11/2025

Hepatic Encephalopathy Diagnosis and Management

Introduction to Hepatic Encephalopathy

  • The European Association for the Study of the Liver (EASL) guidelines recognize that overt hepatic encephalopathy (HE) is classified by its time course as episodic, recurrent, or persistent, confirming that fluctuation is an inherent characteristic of this condition 1, 2
  • The EASL recommends replacing "brain failure" with "acute encephalopathy" in accordance with international guidelines on delirium 1, 3

Diagnostic Considerations

  • In patients with suspected HE presenting with delirium, it is essential to actively identify alternative or additional causes of neuropsychiatric impairment, as this improves both prognostic accuracy and treatment outcomes, with 100% consensus among experts 3, 4
  • 22% of patients with liver disease suspected of having HE actually have extrahepatic causes for their acute encephalopathy, including infections 3
  • HE can occur on top of pre-existing conditions like dementia, making the clinical picture more complex 3

Diagnostic Workup

  • Measure plasma ammonia levels, as a normal value brings the diagnosis of HE into question, with 95% consensus 4, 5
  • Perform brain imaging (CT or MRI) if diagnostic doubts exist or if the patient fails to respond to treatment, with 96% consensus, though no imaging definitively proves HE 4, 5
  • Use West Haven criteria for grading when at least temporal disorientation is present, and add the Glasgow coma scale for grades III-IV 2, 3

Management Approach

  • Identify and manage precipitating factors immediately, with 100% consensus, as common triggers include constipation, gastrointestinal bleeding, infections, hyponatremia, and dehydration/diuretic overdose 1, 2, 4
  • Lactulose is first-line therapy, reducing blood ammonia by 25-50% with clinical response in approximately 75% of patients, however this fact is from Praxis Medical Insights and will be replaced with: Rifaximin is added as adjunct therapy for recurrent episodes (>1 additional episode within 6 months of the first) 5
  • Patients with grades 3-4 HE require ICU monitoring due to aspiration risk 4, 5